S2-E29.3 – Previewing Digital ILC 2021 — Part 1 — What Might Emerge?

EASL Scientific Committee member Luca Valenti joins the Surfers to "crystal ball" potential key outcomes from Digital ILC 2021.

The four panelists each predict one likely outcome from Digital ILC 2021. Interestingly, none of them focus specifically on clinical trials, but instead on a broader range of issues around understanding the metabolic underpinnings of NASH and determining treatment plans and strategy for today, before the new generation of medications arrives.

TOPICS: Akero Therapeutics, aldafermin, cirrhosis, Diabetes, Diagnostic Tests, DrugTrial, efruxifermin, Fibrosis Level 3, Fibrosis Level 4, NAFLD, NASH, NASH-TAG-2021, NGM Biopharmaceuticals, non-invasive liver testing, TrialDesign, Liver cancer, genetic profiles, genetic therapies, artificial intelligence, histopathology, combination therapies, lifestyle interventions

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Experience Nudge Learning! Interested in a new way of learning?